Overview

Boston Therapeutics, Inc. (OTCQB: BTHE)

Boston Therapeutics, headquartered in Manchester, NH, Boston Therapeutics, Inc. is a pharmaceutical company focused on the development, manufacture and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs in the areas of diabetes and inflammatory diseases.

The Company's initial product pipeline is focused on developing and commercializing therapeutic molecules: PAZ320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation; and IPOXYN™, a systemic, injectable complex carbohydrate-based drug for prevention of necrosis and treatment of limb ischemia.

Quick Links

Investor Presentation	10-Q	10-K

Recent News

Share Statistics

Outstanding: 19,363,539
(as of May 7, 2013)

Company Information

Boston Therapeutics, Inc.
1750 Elm Street
Suite 103
Manchester
NH 03104

Investor Relations

Boston Therapeutics, Inc.
Anthony Squeglia
Director of Strategic Planning and Investor Relations
1750 Elm Street
Suite 103
Manchester, NH 03104
(603) 935-9799
(603) 685-4784 fax
anthony.squeglia@bostonti.com

Transfer Agent

Worldwide Stock Transfer, LLC
Yonah Kopstick
433 Hackensack Avenue
Level L
Hackensack, NJ 07601
(210) 820-2008
www.wwstr.com

Auditors

McGladrey, LLP
80 City Square
Boston, MA 02129